The cancer anorexia-cachexia syndrome: myth or reality?

被引:32
|
作者
Lasheen, Wael [2 ]
Walsh, Declan [1 ,2 ]
机构
[1] Cleveland Clin, Cleveland, OH 44195 USA
[2] Taussig Canc Inst, Cleveland Clin, Dept Solid Tumor Oncol, Harry R Horvitz Ctr Palliat Med, Cleveland, OH USA
关键词
Cancer; Cachexia; Anorexia; Anorexia-cachexia; Symptoms; Symptom burden; Survival; Prognosis; Palliative care; MEGESTROL-ACETATE; WEIGHT-LOSS; FOOD-INTAKE; CHEMOTHERAPY; DEFINITION; SYMPTOMS; THERAPY; PLACEBO;
D O I
10.1007/s00520-009-0772-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Controversy exists as what constitutes the cancer anorexia-cachexia syndrome (CACS), and whether it truly is a distinct clinical disorder. In this study, we aimed to: (1) assess if CACS is a distinct clinical disorder, (2) identify the symptoms characteristic of CACS, (3) evaluate CACS impact on patient outcomes (symptom burden and survival time from referral). Consecutive patients referred to palliative medicine were assessed by 38-symptom questionnaire. Demographics, Eastern Cooperative Oncology Group (ECOG), disease and extent, and survival were recorded. CACS, defined as anorexia plus weight loss (> 10% of pre-illness weight). For analysis, patients were divided into four groups: (1) group CACS; (2) group A (only anorexia, NO > 10% pre-illness weight loss); (3) group WL (weight loss > 10% pre-illness weight only but NO anorexia); and (4) group N (NO weight loss > 10% pre-illness weight and NO anorexia). Symptoms present in a parts per thousand yen5%, and patients with complete data were analyzed. Four hundred eighty-four patients had complete data, metastatic cancer, and 26 symptoms present in a parts per thousand yen5%. Groups had significantly different ECOG, symptom burden, and survival. Significantly different symptom prevalence between groups: dry mouth,*early satiety,*constipation,*nausea,*taste changes,*vomiting,*dysphagia,*fatigue,*weak,*lack of energy, insomnia, dyspnea, depression, hoarseness, and anxiety. The nine symptoms with asterisk were CACS specific. Symptom Burden: CACS independently predicted greatest burden. Survival: Group N had significantly longer survival. CACS appeared to be a distinct disorder with unique clinical characteristics in our advanced cancer population. Nine other symptoms constituted CACS. CACS independently predicted higher symptom burden. CACS absence predicted longer survival. More evidence is needed to better characterize this syndrome and generate a valid CACS consensus. A comprehensive validated CACS assessment instrument is required.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 50 条
  • [41] Audit of symptoms and prescribing in patients with the anorexia-cachexia syndrome
    Andrew, Inga
    Kirkpatrick, Graeme
    Holden, Keith
    Hawkins, Colette
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 489 - 496
  • [42] Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis
    Zhan, Ping
    Wang, Qin
    Qian, Qian
    Yu, Li-Ke
    TRANSLATIONAL CANCER RESEARCH, 2013, 2 (02) : 74 - 79
  • [43] Anorexia-cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach
    Ronga, Ilaria
    Gallucci, Fernando
    Riccardi, Ferdinando
    Uomo, Generoso
    ADVANCES IN MEDICAL SCIENCES, 2014, 59 (01): : 1 - 6
  • [44] Leveraging a Team Mental Model to Develop a Cancer Anorexia-Cachexia Syndrome Team
    Portman, Diane G.
    Thirlwell, Sarah
    Donovan, Kristine A.
    Alvero, Christine
    Gray, Jhanelle E.
    Holloway, Rosa
    Ellington, Lee
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1046 - +
  • [45] Cancer anorexia-cachexia syndrome is characterized by more than one inflammatory pathway
    Gagnon, Bruno
    Murphy, Jessica
    Simonyan, David
    Penafuerte, Claudia A.
    Sirois, Jacinthe
    Chasen, Martin
    Tremblay, Michel L.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (03) : 1041 - 1053
  • [46] Corticotropin-Releasing Factor: A Key Element in Cancer Anorexia-Cachexia Syndrome
    Tsai, Minglun
    Fujitsuka, Naoki
    Amitani, Marie S.
    Amitani, Haruka
    Asakawa, Akihiro
    Hattori, Tomohisa
    Kase, Yoshio
    Inui, Akio
    GASTROENTEROLOGY, 2011, 140 (05) : S477 - S477
  • [47] Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
    Bai, Yu
    Hu, Yunxia
    Zhao, Yanhua
    Yu, Xizhong
    Xu, Junwei
    Hua, Zhiyun
    Zhao, Zhiqiang
    SUPPORTIVE CARE IN CANCER, 2017, 25 (05) : 1651 - 1659
  • [48] Evidence for partial pharmaceutical reversal of the cancer anorexia-cachexia syndrome: the case of anamorelin
    Anker, Stefan D.
    Coats, Andrew J. S.
    Morley, John E.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2015, 6 (04) : 275 - 277
  • [49] Family Members' Explanatory Models of Cancer Anorexia-Cachexia
    McClement, Susan
    HEALTHCARE, 2024, 12 (16)
  • [50] Brainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat
    Borner, Tito
    Liberini, Claudia G.
    Lutz, Thomas A.
    Riediger, Thomas
    NEUROPHARMACOLOGY, 2018, 131 : 282 - 290